The patient was readmitted due to recurrent epistaxis, hemoptysis, and cough on day 26 after coronary stenting. HgB and the AUCs of aspirin and ticagrelor were 10.7 g/dL, 19, and 22, respectively, whereas PT, PTT, and factor V activity showed no significant changes (Fig. 2). Due to the recurrent epistaxis and oozing of the nasal mucus membrane, the aspirin was stopped and only the daily maintenance dose of 90 mg of ticagrelor was maintained. HgB remained constant at 9.5 g/dL, and epistaxis and hemoptysis both stopped. The factor V activity and AUC value of ticagrelor 5 days after stopping aspirin were 12 and 52, respectively. After symptoms improved, she was discharged on day 35 with only 90 mg of ticagrelor daily.